|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||||||||||
| Land | ||||||||||||||||||||
| Income producing property, at cost | ||||||||||||||||||||
| Accumulated depreciation and amortization | ||||||||||||||||||||
| Properties under development or held for future development | ||||||||||||||||||||
| Total real estate held for investment, net | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Restricted cash | ||||||||||||||||||||
| Income producing property | ||||||||||||||||||||
| Cash, cash equivalents and restricted cash | ||||||||||||||||||||
| Rents and other receivables | ||||||||||||||||||||
| Prepaid expenses and other assets | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| Liabilities | ||||||||||||||||||||
| Liabilities for estimated costs in excess of estimated receipts during liquidation | ||||||||||||||||||||
| Debt payable | ||||||||||||||||||||
| Line of credit | ||||||||||||||||||||
| Accounts payable and accrued expenses | ||||||||||||||||||||
| Dividend payable | ||||||||||||||||||||
| Advance rents | ||||||||||||||||||||
| Tenant security deposits | ||||||||||||||||||||
| Liquidating distribution payable | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| Preferred shares; $0.01 par value; 10,000 shares authorized; no shares issued or outstanding | ||||||||||||||||||||
| Shares of beneficial interest, $0.01 par value; 150,000 shares authorized: 88,029 shares issued and outstanding as of December 31, 2024 | ||||||||||||||||||||
| Additional paid in capital | ||||||||||||||||||||
| Distributions in excess of net income | ||||||||||||||||||||
| Accumulated other comprehensive loss | ||||||||||||||||||||
| Total shareholders’ equity | ||||||||||||||||||||
| Noncontrolling interests in subsidiaries | ||||||||||||||||||||
| Total equity | ||||||||||||||||||||
| Total liabilities and equity | ||||||||||||||||||||
| Shares of beneficial interest, authorized (in shares) | ||||||||||||||||||||
| Net assets in liquidation | ||||||||||||||||||||
Loading...
